Literature DB >> 15992458

The "emigration, migration, and immigration"of prostate cancer.

Kenneth J Pienta1, Robert Loberg.   

Abstract

In the vast majority of cases, cancer continues to be an incurable disease when it has spread beyond the primary organ. Most cancer research and therapy design to date has focused on chemotherapy directed at killing the replicating tumor cells. Little attention has been placed on targeting the microenvironments of the primary tumor site, the circulating tumor cells, or the metastatic or secondary (target) tumor site and how cancer cells move among them. To develop these targets, a better understanding of metastasis and the mechanisms underlying the spread of tumors is required. This review describes the steps of metastasis using a paradigm of emigration to migration to immigration, with prostate cancer as a model system.

Entities:  

Mesh:

Year:  2005        PMID: 15992458     DOI: 10.3816/cgc.2005.n.008

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN: 1540-0352


  26 in total

Review 1.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

Review 2.  Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?

Authors:  Ana Sofia Azevedo; Gautier Follain; Shankar Patthabhiraman; Sébastien Harlepp; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2015-08-27       Impact factor: 3.405

3.  Mechanosensitive Ca(2+) permeant cation channels in human prostate tumor cells.

Authors:  Rosario Maroto; Alexander Kurosky; Owen P Hamill
Journal:  Channels (Austin)       Date:  2012-07-01       Impact factor: 2.581

4.  Disrupting the networks of cancer.

Authors:  Daniel F Camacho; Kenneth J Pienta
Journal:  Clin Cancer Res       Date:  2012-03-22       Impact factor: 12.531

Review 5.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Authors:  Jian Zhang; Yi Lu; Kenneth J Pienta
Journal:  J Natl Cancer Inst       Date:  2010-03-16       Impact factor: 13.506

Review 6.  Mechanisms of cancer cell metastasis to the bone: a multistep process.

Authors:  Lalit R Patel; Daniel F Camacho; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Future Oncol       Date:  2011-11       Impact factor: 3.404

7.  CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

Authors:  Hernan Roca; Zachary S Varsos; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.

Authors:  Kenneth J Pienta; Natalie McGregor; Robert Axelrod; David E Axelrod
Journal:  Transl Oncol       Date:  2008-12       Impact factor: 4.243

9.  CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.

Authors:  Hernan Roca; Zachary Varsos; Kenneth J Pienta
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

10.  Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.

Authors:  S Dasgupta; L M Wasson; N Rauniyar; L Prokai; J Borejdo; J K Vishwanatha
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.